Erika L. Beroncal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erika L. Beroncal has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ana Cristina Andreazza
Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada
2 shared publications - Aadil Ali
Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
1 shared publication Agostino Pierro
Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
1 shared publication- Aizhou Wang
Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
1 shared publication - Andrew Baker
University of Toronto
1 shared publication - Bo Li
Translational Medicine, The Hospital for Sick Children, 686 Bay Street, Toronto, Ontario, M5G0A4, Canada
1 shared publication
Latest Publications
- Open Access
- 19 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Itaconate supplementation leads to improvement in donor lung function after extended hypothermic preservation
- 19 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Open AccessItaconate supplementation leads to improvement in donor lung function after extended hypothermic preservation
- Open Access
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eadk0164
Cardiac tissue model of immune-induced dysfunction reveals the role of free mitochondrial DNA and the therapeutic effects of exosomes
Despite tremendous progress in the development of mature heart-on-a-chip models, human cell–based models of myocardial inflammation are lacking. Here, we bioengineered a vascularized heart-on-a-chip with circulating immune cells to model severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–induced acute myocarditis. We observed hallmarks of coronavirus disease (COVID-19)–induced myocardial inflammation, as the presence of immune cells augmented the secretion of proinflammatory cytokines, triggered progressive impairment of contractile function, and altered intracellular calcium transients. An elevation of circulating cell-free mitochondrial DNA (ccf-mtDNA) was measured first in the heart-on-a-chip and then validated in COVID-19 patients with low left ventricular ejection fraction, demonstrating that mitochondrial damage is an important pathophysiological hallmark of inflammation-induced cardiac dysfunction. Leveraging this platform in the context of SARS-CoV-2–induced myocardial inflammation, we established that administration of endothelial cell–derived exosomes effectively rescued the contractile deficit, normalized calcium handling, elevated the contraction force, and reduced the ccf-mtDNA and cytokine release via Toll-like receptor–nuclear factor κB signaling axis.
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eadk0164
Open AccessCardiac tissue model of immune-induced dysfunction reveals the role of free mitochondrial DNA and the therapeutic effects of exosomes
Despite tremendous progress in the development of mature heart-on-a-chip models, human cell–based models of myocardial inflammation are lacking. Here, we bioengineered a vascularized heart-on-a-chip with circulating immune cells to model severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–induced acute myocarditis. We observed hallmarks of coronavirus disease (COVID-19)–induced myocardial inflammation, as the presence of immune cells augmented the secretion of proinflammatory cytokines, triggered progressive impairment of contractile function, and altered intracellular calcium transients. An elevation of circulating cell-free mitochondrial DNA (ccf-mtDNA) was measured first in the heart-on-a-chip and then validated in COVID-19 patients with low left ventricular ejection fraction, demonstrating that mitochondrial damage is an important pathophysiological hallmark of inflammation-induced cardiac dysfunction. Leveraging this platform in the context of SARS-CoV-2–induced myocardial inflammation, we established that administration of endothelial cell–derived exosomes effectively rescued the contractile deficit, normalized calcium handling, elevated the contraction force, and reduced the ccf-mtDNA and cytokine release via Toll-like receptor–nuclear factor κB signaling axis.